eli lilly oral glp 1 GLP-1 Orforglipron Is Approved for Obesity Lilly's GLP-1 pill outperforms Novo's

Previous studies have shown people with a BMI 40, also known as class 3 obesity, and women have an increased risk of thyroid cancer

Revolutionizing GLP-1 delivery with sublingual administration Recently, a new sublingual modality for GLP-1 receptor agonists (and also for insulins) delivery has been developed by the Dutch company SUBLIN BV, established in 2018 as a spin-out of the healthcare branch of NanoServe BV

Any changes in sexual function are likely related to weight loss, hormonal normalization, improved body image, and enhanced metabolic health rather than a direct medication effect

Shes the lady to see!!! Rich R

Clinical trial data show it helps 37% of people lose at least 5% of their starting body weight in 12 weeks

Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes